Exact Mass: 307.178349

Exact Mass Matches: 307.178349

Found 103 metabolites which its exact mass value is equals to given mass value 307.178349, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Zolpidem

N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate

C19H21N3O (307.1684536)


Some users take zolpidem recreationally for these side effects. However, it may be less common than benzodiazepine abuse. In the United States, recreational use may be less common than in countries where the drug is available as a less expensive generic. Zolpidem can become addictive if taken for extended periods of time, due to dependence on its ability to put one to sleep or to the euphoria it can sometimes produce. Like most addictive drugs, a tolerance in the zolpidem user develops and increases all the more quickly the longer she or he has been regularly taking it. Under the influence of the drug it is common to take more zolpidem than is necessary due to either forgetting that one has already taken a pill (elderly users are particularly at risk here), or knowingly taking more than the prescribed dosage. Users with a predilection for abuse are advised to keep additional zolpidem in a safe place that is unlikely to be remembered or accessed while intoxicated to avoid this risk. A trustworthy friend or relative is the best defense if such people are available; otherwise, a box or cupboard locked with a combination padlock is a good defense against this tendency, as the abovementioned side-effects can easily prevent a user from operating such a lock while under the drugs influence; Zolpidem is a prescription drug used for the short-term treatment of insomnia. It works quickly (usually within 15 minutes) and has a short half-life (2-3 hours). Some trade names of zolpidem are Ambien, Stilnox, Stilnoct, Hypnogen or Myslee. Its hypnotic effects are similar to those of the benzodiazepines, but it is classified as an imidazopyridine, and the anticonvulsant and muscle relaxant effects only appear at 10 and 20 times the dose required for sedation, respectively. For that reason, it has never been approved for either muscle relaxation or seizure prevention. Such drastically increased doses are more likely to induce one or more negative side effects, including hallucinations and/or amnesia. (See below.); Some users take zolpidem recreationally for these side effects. However, it may be less common than benzodiazepine abuse. In the United States, recreational use may be less common than in countries where the drug is available as a less expensive generic. Zolpidem can become addictive if taken for extended periods of time, due to dependence on its ability to put one to sleep or to the euphoria it can sometimes produce. Like most addictive drugs, a tolerance in the zolpidem user develops and increases all the more quickly the longer she or he has been regularly taking it. Under the influence of the drug it is common to take more zolpidem than is necessary due to either forgetting that one has already taken a pill (elderly users are particularly at risk here), or knowingly taking more than the prescribed dosage. Users with a predilection for abuse are advised to keep additional zolpidem in a safe place that is unlikely to be remembered or accessed while intoxicated to avoid this risk. A trustworthy friend or relative is the best defense if such people are available; Recreational zolpidem use is speculated to lead to tolerance and dependence much more quickly than prescribed use. Recreational use is rising, as demonstrated by the use of street names for the pill, such as: A (which is most likely due to the imprint on the Ambien CR brand of zolpidem, which consists of a capital A along with a tilde, which looks roughly like A~, as well as for sedative and calming effects, A+ is a street name for Adderall, named so because of its stimulant effects) and zombie pills (because of the waking sleep/sensory deprivation effect some users have reported experiencing). Another buzz term for Ambien is tic-tacs, referring to the shape and color of commonly abused 10mg tablets; Zolpidem is a prescription drug used for the short-term treatment of insomnia. It works quickly (usually within 15 minutes) and has a short half-life (2-3 hours). Its hypnotic eff... Zolpidem (sold under the brand names Ambien, Ambien CR, Stilnox, and Sublinox) is a prescription medication used for the treatment of insomnia, as well as some brain disorders. It is a short-acting nonbenzodiazepine hypnotic of the imidazopyridine class that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to GABAA receptors at the same location as benzodiazepines. It works quickly (usually within 15 minutes) and has a short half-life (two to three hours). Zolpidem has not adequately demonstrated effectiveness in maintaining sleep (unless delivered in a controlled-release form); however, it is effective in initiating sleep. Some users take zolpidem recreationally for these side effects. However, it may be less common than benzodiazepine abuse. Zolpidem can become addictive if taken for extended periods of time, due to dependence on its ability to put one to sleep or to the euphoria it can sometimes produce. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CF - Benzodiazepine related drugs D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018755 - GABA Agonists C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic

   
   

DTAB

Dodecyltrimethylammonium bromide

C15H34BrN (307.1874464)


D013501 - Surface-Active Agents > D003902 - Detergents

   

Ibopamine

[4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate

C17H25NO4 (307.178349)


Ibopamine is a sympathomimetic used in ophthalmology. It induces mydriasis. It also has been investigated for use in the treatment of congestive heart failure. C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents S - Sensory organs > S01 - Ophthalmologicals > S01F - Mydriatics and cycloplegics > S01FB - Sympathomimetics excl. antiglaucoma preparations D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents D045283 - Natriuretic Agents > D004232 - Diuretics

   

Alcaftadine

2-(1-methylpiperidin-4-ylidene)-4,7-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3,5,10,12-pentaene-6-carbaldehyde

C19H21N3O (307.1684536)


Alcaftadine is only found in individuals that have used or taken this drug. It is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.Alcaftadine is a H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated. C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Alcaftadine (R89674) is a histamine H1 receptor antagonist, which is used to prevent eye irritation brought on by allergic conjunctivitis. Alcaftadine is a broad-spectrum antihistamine displaying a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors. Alcaftadine also exhibits modulatory action on immune cell recruitment and mast cell stabilizing effects[1][2].

   

Talastine

4-benzyl-2-[2-(dimethylamino)ethyl]-1,2-dihydrophthalazin-1-one

C19H21N3O (307.1684536)


R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AB - Substituted alkylamines C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Talastine is a first-generation alkylamine H1-antihistamine.

   

4-Phenylbutanoylcarnitine

3-[(4-phenylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H25NO4 (307.178349)


4-Phenylbutanoylcarnitine is an acylcarnitine. More specifically, it is an 4-phenylbutanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Phenylbutanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Phenylbutanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dhlnl

2-amino-6-[(5-amino-5-carboxy-2-hydroxypentyl)amino]-5-hydroxyhexanoic acid

C12H25N3O6 (307.174327)


   

Buflomedil

4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one

C17H25NO4 (307.178349)


C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor

   

N-(1-Adamantyl)quinoxaline-2-carboxamide

N-(adamantan-1-yl)quinoxaline-2-carboxamide

C19H21N3O (307.1684536)


NPS 2390 is a noncompetitive antagonist of mGluR1 and mGluR5[1]. NPS 2390 is also a potent CaSR (calcium-sensing receptor) inhibitor[2][3].

   

2-[(3-Phenyl-5,6-dihydro-2h-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydroisoquinoline

2-[(3-Phenyl-5,6-dihydro-2h-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydroisoquinoline

C19H21N3O (307.1684536)


   

Trocimine

N-(3,4,5-Trimethoxybenzoyl)azocidine

C17H25NO4 (307.178349)


   
   

Antibiotic TS 885

9-Methylstreptimidone

C17H25NO4 (307.178349)


   

(+)-N-Acetylparthenolidine

(+)-N-Acetylparthenolidine

C17H25NO4 (307.178349)


   

4-Hydroxydendroxine

4-Hydroxydendroxine

C17H25NO4 (307.178349)


   
   

6-Hydroxydendroxine

6-Hydroxydendroxine

C17H25NO4 (307.178349)


   
   

Buflomedil

Buflomedil

C17H25NO4 (307.178349)


C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor CONFIDENCE standard compound; EAWAG_UCHEM_ID 3068

   

Evodiamide

N-[2-(1H-indol-3-yl)ethyl]-N-methyl-2-methylamino-benzamide

C19H21N3O (307.1684536)


   
   

2-(3,5-Dimethyl-2-oxo-4,6-octadienyl)tetrahydro-6-oxo-2H-pyran-4-acetamide

2-(3,5-Dimethyl-2-oxo-4,6-octadienyl)tetrahydro-6-oxo-2H-pyran-4-acetamide

C17H25NO4 (307.178349)


   

sessilifoliamide A

sessilifoliamide A

C17H25NO4 (307.178349)


   

1,9-epoxy-9a-hydroxystenine

1,9-epoxy-9a-hydroxystenine

C17H25NO4 (307.178349)


   

N-coronafacoyl-valine

N-coronafacoyl-valine

C17H25NO4 (307.178349)


   

4-O-(6-Amino-6-deoxyglucopyranosyl)-2,5-dideoxystreptamine

4-O-(6-Amino-6-deoxyglucopyranosyl)-2,5-dideoxystreptamine

C12H25N3O6 (307.174327)


   
   

1-(2-hydroxy-3-methyl)-butyl-hydrocotarnine

NCGC00160253-01!1-(2-hydroxy-3-methyl)-butyl-hydrocotarnine

C17H25NO4 (307.178349)


   

zolpidem

zolpidem

C19H21N3O (307.1684536)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CF - Benzodiazepine related drugs D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018755 - GABA Agonists C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic

   
   

C-7-methyl substituted CFA-Ile

C-7-methyl substituted CFA-Ile

C17H25NO4 (307.178349)


   

Alcaftadine

2-(1-methylpiperidin-4-ylidene)-4,7-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(14),3,5,10,12-pentaene-6-carbaldehyde

C19H21N3O (307.1684536)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Alcaftadine (R89674) is a histamine H1 receptor antagonist, which is used to prevent eye irritation brought on by allergic conjunctivitis. Alcaftadine is a broad-spectrum antihistamine displaying a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors. Alcaftadine also exhibits modulatory action on immune cell recruitment and mast cell stabilizing effects[1][2].

   

Ibopamine

[4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate

C17H25NO4 (307.178349)


C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents S - Sensory organs > S01 - Ophthalmologicals > S01F - Mydriatics and cycloplegics > S01FB - Sympathomimetics excl. antiglaucoma preparations D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents D045283 - Natriuretic Agents > D004232 - Diuretics

   

ETHYL 4-(BENZYL(2-ETHOXY-2-OXOETHYL)AMINO)BUTANOATE

ETHYL 4-(BENZYL(2-ETHOXY-2-OXOETHYL)AMINO)BUTANOATE

C17H25NO4 (307.178349)


   

Trocimine

Methanone,(hexahydro-1(2H)-azocinyl)(3,4,5-trimethoxyphenyl)-

C17H25NO4 (307.178349)


C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent

   

1-BOC-4-(2-METHOXYPHENYL)-4-HYDROXYPIPERIDINE

1-BOC-4-(2-METHOXYPHENYL)-4-HYDROXYPIPERIDINE

C17H25NO4 (307.178349)


   
   

METHYL 2-N-BOC-2-AMINOMETHYL)-3-M-TOLYL-PROPIONATE

METHYL 2-N-BOC-2-AMINOMETHYL)-3-M-TOLYL-PROPIONATE

C17H25NO4 (307.178349)


   

ETHYL 4-((1-METHYLPIPERIDIN-4-YL)METHOXY)-3-METHOXYBENZOATE

ETHYL 4-((1-METHYLPIPERIDIN-4-YL)METHOXY)-3-METHOXYBENZOATE

C17H25NO4 (307.178349)


   

4-[6-(4-propan-2-ylpiperazin-1-yl)pyridazin-3-yl]benzonitrile

4-[6-(4-propan-2-ylpiperazin-1-yl)pyridazin-3-yl]benzonitrile

C18H21N5 (307.1796866)


   

Lithium triisopropyl 2-(5-chloropyridyl)borate

Lithium triisopropyl 2-(5-chloropyridyl)borate

C14H24BClLiNO3 (307.16977240000006)


   

methyl 2-[(4-methylphenyl)methyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate

methyl 2-[(4-methylphenyl)methyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate

C17H25NO4 (307.178349)


   

N-DESETHYL AMODIAQUINE

N-DESETHYL AMODIAQUINE

C19H21N3O (307.1684536)


   

N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzylidene]benzenamine

N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzylidene]benzenamine

C19H22BNO2 (307.1743502)


   

4-Hydroxy-N-[3-(triethoxysilyl)propyl]butanamide

4-Hydroxy-N-[3-(triethoxysilyl)propyl]butanamide

C13H29NO5Si (307.1814904)


   

BOC-P-ISOPROPYLPHENYL-L-ALANINE

BOC-P-ISOPROPYLPHENYL-L-ALANINE

C17H25NO4 (307.178349)


   

1H-Pyrrolo[2,3-b]pyridin-5-amine, 4-fluoro-1-[tris(1-methylethyl)silyl]-

1H-Pyrrolo[2,3-b]pyridin-5-amine, 4-fluoro-1-[tris(1-methylethyl)silyl]-

C16H26FN3Si (307.1879928)


   

2-(4-N-Boc-piperazino)pyridine-5-boronicacid

2-(4-N-Boc-piperazino)pyridine-5-boronicacid

C14H22BN3O4 (307.17032820000003)


   

b-Alanine,N-(3-methoxy-2-methyl-3-oxopropyl)-N-(phenylmethyl)-, ethyl ester

b-Alanine,N-(3-methoxy-2-methyl-3-oxopropyl)-N-(phenylmethyl)-, ethyl ester

C17H25NO4 (307.178349)


   

4-[2-(4-propan-2-ylpiperazin-1-yl)pyrimidin-5-yl]benzonitrile

4-[2-(4-propan-2-ylpiperazin-1-yl)pyrimidin-5-yl]benzonitrile

C18H21N5 (307.1796866)


   

2-N-BOC-2-METHYLAMINOMETHYL-3-M-TOLYL-PROPIONIC ACID

2-N-BOC-2-METHYLAMINOMETHYL-3-M-TOLYL-PROPIONIC ACID

C17H25NO4 (307.178349)


   

2-N-BOC-2-METHYLAMINOMETHYL-3-P-TOLYL-PROPIONIC ACID

2-N-BOC-2-METHYLAMINOMETHYL-3-P-TOLYL-PROPIONIC ACID

C17H25NO4 (307.178349)


   

b-Alanine,N-(3-ethoxy-3-oxopropyl)-N-(phenylmethyl)-, ethyl ester

b-Alanine,N-(3-ethoxy-3-oxopropyl)-N-(phenylmethyl)-, ethyl ester

C17H25NO4 (307.178349)


   

4-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine

4-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine

C16H23BFNO3 (307.1754930000001)


   

(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridin-4-yl)boronic acid

(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridin-4-yl)boronic acid

C14H22BN3O4 (307.17032820000003)


   

Valsartan Impurity 10

Valsartan Impurity 10

C18H21N5 (307.1796866)


   

n-Octyl-O-(3-(Dimethylchlorosilyl)Propyl)Carbamate

n-Octyl-O-(3-(Dimethylchlorosilyl)Propyl)Carbamate

C14H30ClNO2Si (307.17342299999996)


   

Ethyl 2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)amino)acetate

Ethyl 2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)amino)acetate

C14H22BN3O4 (307.17032820000003)


   

5-(1-Piperidinylmethyl)thiophene-2-boronic acid pinacol ester

5-(1-Piperidinylmethyl)thiophene-2-boronic acid pinacol ester

C16H26BNO2S (307.17772060000004)


   

(2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)pyridin-3-yl)boronic acid

(2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)pyridin-3-yl)boronic acid

C14H22BN3O4 (307.17032820000003)


   

1-(4-Methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinolin e hydrochloride (1:1)

1-(4-Methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinolin e hydrochloride (1:1)

C18H26ClNO (307.1702816)


   

3-((TERT-BUTOXYCARBONYL)AMINO)-3-(4-ISOPROPYLPHENYL)PROPANOIC ACID

3-((TERT-BUTOXYCARBONYL)AMINO)-3-(4-ISOPROPYLPHENYL)PROPANOIC ACID

C17H25NO4 (307.178349)


   

5,5-Dihydroxylysinonorleucine

5,5-Dihydroxylysinonorleucine

C12H25N3O6 (307.174327)


   
   

2-((1-Oxododecyl)amino)ethanesulphonic acid

2-((1-Oxododecyl)amino)ethanesulphonic acid

C14H29NO4S (307.1817194)


   

7-Methyl-3-(morpholinomethyl)-2-phenylimidazo[1,2-a]pyridine

7-Methyl-3-(morpholinomethyl)-2-phenylimidazo[1,2-a]pyridine

C19H21N3O (307.1684536)


   

N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine

N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine

C18H21N5 (307.1796866)


   

Talastine

Talastine

C19H21N3O (307.1684536)


R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AB - Substituted alkylamines C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist

   

1-(4-Hydroxy-3-methoxycinnamoylamino)-4-guanidinobutane

1-(4-Hydroxy-3-methoxycinnamoylamino)-4-guanidinobutane

C15H23N4O3+ (307.17700679999996)


   

4-Phenylbutanoylcarnitine

4-Phenylbutanoylcarnitine

C17H25NO4 (307.178349)


   

1-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3-methylbutan-2-ol

1-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3-methylbutan-2-ol

C17H25NO4 (307.178349)


   

3-Methyl-2-[[oxo-(4-pentoxyphenyl)methyl]amino]butanoic acid

3-Methyl-2-[[oxo-(4-pentoxyphenyl)methyl]amino]butanoic acid

C17H25NO4 (307.178349)


   

4-Ethyl-2-methoxy-3-phenyl-3,3a,9,9a-tetrahydropyrrolo[2,3-b]quinoxaline

4-Ethyl-2-methoxy-3-phenyl-3,3a,9,9a-tetrahydropyrrolo[2,3-b]quinoxaline

C19H21N3O (307.1684536)


   

(2S,3S,4R)-4-cyclopropyl-2-ethoxy-3-(3-hydroxypropyl)-N-prop-2-ynyl-3,4-dihydro-2H-pyran-6-carboxamide

(2S,3S,4R)-4-cyclopropyl-2-ethoxy-3-(3-hydroxypropyl)-N-prop-2-ynyl-3,4-dihydro-2H-pyran-6-carboxamide

C17H25NO4 (307.178349)


   

N-dodecanoyltaurine

N-dodecanoyltaurine

C14H29NO4S (307.1817194)


A fatty acid-taurine conjugate derived from dodecanoic acid.

   
   
   

2-{[(6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl)(hydroxy)methylidene]amino}-3-methylbutanoic acid

2-{[(6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl)(hydroxy)methylidene]amino}-3-methylbutanoic acid

C17H25NO4 (307.178349)


   

18-methyl-3,13,19-triazapentacyclo[11.7.1.0²,¹⁰.0⁴,⁹.0¹⁷,²¹]henicosa-2(10),4,6,8,16,19-hexaen-20-ol

18-methyl-3,13,19-triazapentacyclo[11.7.1.0²,¹⁰.0⁴,⁹.0¹⁷,²¹]henicosa-2(10),4,6,8,16,19-hexaen-20-ol

C19H21N3O (307.1684536)


   

6-hydroxy-16-isopropyl-15-methyl-3,14-dioxa-11-azapentacyclo[7.5.1.1²,⁵.0¹,¹¹.0⁶,¹⁵]hexadecan-4-one

6-hydroxy-16-isopropyl-15-methyl-3,14-dioxa-11-azapentacyclo[7.5.1.1²,⁵.0¹,¹¹.0⁶,¹⁵]hexadecan-4-one

C17H25NO4 (307.178349)


   

(5e,8r,9e)-3-(2-methoxy-2-oxoethyl)-8,10-dimethyl-7-oxododeca-5,9,11-trienimidic acid

(5e,8r,9e)-3-(2-methoxy-2-oxoethyl)-8,10-dimethyl-7-oxododeca-5,9,11-trienimidic acid

C17H25NO4 (307.178349)


   

(1s,18r,21r)-18-methyl-3,13,19-triazapentacyclo[11.7.1.0²,¹⁰.0⁴,⁹.0¹⁷,²¹]henicosa-2(10),4,6,8,16,19-hexaen-20-ol

(1s,18r,21r)-18-methyl-3,13,19-triazapentacyclo[11.7.1.0²,¹⁰.0⁴,⁹.0¹⁷,²¹]henicosa-2(10),4,6,8,16,19-hexaen-20-ol

C19H21N3O (307.1684536)


   

(2s)-2-({[(3ar,6r,7ar)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl](hydroxy)methylidene}amino)-3-methylbutanoic acid

(2s)-2-({[(3ar,6r,7ar)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl](hydroxy)methylidene}amino)-3-methylbutanoic acid

C17H25NO4 (307.178349)


   

(1's,2'r,3's,4s,6'r)-3'-ethyl-4-methyl-5'-oxa-10'-azaspiro[oxolane-2,4'-tricyclo[8.3.0.0²,⁶]tridecane]-5,11'-dione

(1's,2'r,3's,4s,6'r)-3'-ethyl-4-methyl-5'-oxa-10'-azaspiro[oxolane-2,4'-tricyclo[8.3.0.0²,⁶]tridecane]-5,11'-dione

C17H25NO4 (307.178349)


   

n-[2-(1h-indol-3-yl)ethyl]-n-methyl-2-(methylamino)benzamide

n-[2-(1h-indol-3-yl)ethyl]-n-methyl-2-(methylamino)benzamide

C19H21N3O (307.1684536)


   

6-hydroxydendroxine

NA

C17H25NO4 (307.178349)


{"Ingredient_id": "HBIN012430","Ingredient_name": "6-hydroxydendroxine","Alias": "NA","Ingredient_formula": "C17H25NO4","Ingredient_Smile": "CC(C)C1C2C(=O)OC1C34C5(C2(CCC5CN3CCO4)O)C","Ingredient_weight": "307.389","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9983","TCMSP_id": "NA","TCM_ID_id": "7545","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-{2-[(4e,6z)-3,5-dimethyl-2-oxoocta-4,6-dien-1-yl]-6-oxooxan-4-yl}ethanimidic acid

2-{2-[(4e,6z)-3,5-dimethyl-2-oxoocta-4,6-dien-1-yl]-6-oxooxan-4-yl}ethanimidic acid

C17H25NO4 (307.178349)


   

(1r,2r,5s,6r,9s,15s,16s)-6-hydroxy-16-isopropyl-15-methyl-3,14-dioxa-11-azapentacyclo[7.5.1.1²,⁵.0¹,¹¹.0⁶,¹⁵]hexadecan-4-one

(1r,2r,5s,6r,9s,15s,16s)-6-hydroxy-16-isopropyl-15-methyl-3,14-dioxa-11-azapentacyclo[7.5.1.1²,⁵.0¹,¹¹.0⁶,¹⁵]hexadecan-4-one

C17H25NO4 (307.178349)


   

2-{2-[(4e,6e)-3,5-dimethyl-2-oxoocta-4,6-dien-1-yl]-6-oxooxan-4-yl}ethanimidic acid

2-{2-[(4e,6e)-3,5-dimethyl-2-oxoocta-4,6-dien-1-yl]-6-oxooxan-4-yl}ethanimidic acid

C17H25NO4 (307.178349)


   

(1s,2r,3s,6r,11s)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-one

(1s,2r,3s,6r,11s)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-one

C17H25NO4 (307.178349)


   

3-methyl-11-(4-methyl-5-oxooxolan-2-yl)-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-one

3-methyl-11-(4-methyl-5-oxooxolan-2-yl)-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-one

C17H25NO4 (307.178349)


   

9-hydroxy-2-methoxy-6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one

9-hydroxy-2-methoxy-6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one

C17H25NO4 (307.178349)


   

(1s,2r,3s)-3-methyl-11-[(2s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-one

(1s,2r,3s)-3-methyl-11-[(2s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridecan-4-one

C17H25NO4 (307.178349)


   

(2r)-2-({[(3as,6r,7as)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl](hydroxy)methylidene}amino)-3-methylbutanoic acid

(2r)-2-({[(3as,6r,7as)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl](hydroxy)methylidene}amino)-3-methylbutanoic acid

C17H25NO4 (307.178349)


   

6-hydroxy-4-[(6e,8e)-2-hydroxy-5,7-dimethyl-4-oxodeca-6,8-dien-1-yl]-4,5-dihydro-3h-pyridin-2-one

6-hydroxy-4-[(6e,8e)-2-hydroxy-5,7-dimethyl-4-oxodeca-6,8-dien-1-yl]-4,5-dihydro-3h-pyridin-2-one

C17H25NO4 (307.178349)


   

6-hydroxy-4-[(2r,5s,6e,8z)-2-hydroxy-5,7-dimethyl-4-oxodeca-6,8-dien-1-yl]-4,5-dihydro-3h-pyridin-2-one

6-hydroxy-4-[(2r,5s,6e,8z)-2-hydroxy-5,7-dimethyl-4-oxodeca-6,8-dien-1-yl]-4,5-dihydro-3h-pyridin-2-one

C17H25NO4 (307.178349)


   

(1r,2r,5r,6s,9s,15r,16r)-16-hydroxy-16-isopropyl-15-methyl-3,14-dioxa-11-azapentacyclo[7.5.1.1²,⁵.0¹,¹¹.0⁶,¹⁵]hexadecan-4-one

(1r,2r,5r,6s,9s,15r,16r)-16-hydroxy-16-isopropyl-15-methyl-3,14-dioxa-11-azapentacyclo[7.5.1.1²,⁵.0¹,¹¹.0⁶,¹⁵]hexadecan-4-one

C17H25NO4 (307.178349)


   

n-{[(1s,2s,4s,7z,11s,12r)-4,8-dimethyl-13-oxo-3,14-dioxatricyclo[9.3.0.0²,⁴]tetradec-7-en-12-yl]methyl}ethanimidic acid

n-{[(1s,2s,4s,7z,11s,12r)-4,8-dimethyl-13-oxo-3,14-dioxatricyclo[9.3.0.0²,⁴]tetradec-7-en-12-yl]methyl}ethanimidic acid

C17H25NO4 (307.178349)


   

(6s,6ar,8s,9s,10r,10ar)-9-hydroxy-2-methoxy-6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one

(6s,6ar,8s,9s,10r,10ar)-9-hydroxy-2-methoxy-6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one

C17H25NO4 (307.178349)


   

3'-ethyl-4-methyl-5'-oxa-10'-azaspiro[oxolane-2,4'-tricyclo[8.3.0.0²,⁶]tridecane]-5,11'-dione

3'-ethyl-4-methyl-5'-oxa-10'-azaspiro[oxolane-2,4'-tricyclo[8.3.0.0²,⁶]tridecane]-5,11'-dione

C17H25NO4 (307.178349)


   

(1's,2s,2'r,3's,4s,6'r)-3'-ethyl-4-methyl-5'-oxa-10'-azaspiro[oxolane-2,4'-tricyclo[8.3.0.0²,⁶]tridecane]-5,11'-dione

(1's,2s,2'r,3's,4s,6'r)-3'-ethyl-4-methyl-5'-oxa-10'-azaspiro[oxolane-2,4'-tricyclo[8.3.0.0²,⁶]tridecane]-5,11'-dione

C17H25NO4 (307.178349)


   

3-{[(2e,4e,6e,8e)-1,13-dihydroxytetradeca-2,4,6,8-tetraen-1-ylidene]amino}propanoic acid

3-{[(2e,4e,6e,8e)-1,13-dihydroxytetradeca-2,4,6,8-tetraen-1-ylidene]amino}propanoic acid

C17H25NO4 (307.178349)